Dr. Ron Brown
May 28, 2021
Many people praise the arrival of mRNA COVID-19 vaccines as an exponential leap forward in nucleic acid therapeutics, but the very low absolute risk reduction outcomes of the mRNA COVID-19 vaccine clinical trials, 0.7% for the Pfizer-BioNTech and 1.1% for the Moderna vaccines, do not support this assessment. Dr. Ron Brown Discusses Outcome Reporting Bias in COVID-19 mRNA Clinical Trials | Interview - YouTube. A potential technological cause of this disappointing finding likely involves the lipid nanoparticles (LNP) used to encapsulate mRNA that genetically codes for spike proteins of SARS-CoV-2. To be effective, code in the injected LNP-mRNA biomolecule must be translated by the cell ribosomes during biosynthesis of spike proteins, but evidence suggests that cell defense mechanisms provide barriers to this biomolecular interaction within the cell cytoplasm. Injected LNP-mRNA is engulfed by the cell membrane during endocytosis, and an endocytic vesicle (EV) forms around the biomolecule. Some authors suggest LNP-mRNA may undergo endosomal escape from the EV and release its mRNA cargo into the cytoplasm. Cytosolic delivery of nucleic acids...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).